Special Issue

Experimental and Translational Research on Liver Disease

Message from the Guest Editor

Injury to liver is a major contributor to acute hepatic injury. Liver injury of varied etiology may progress to Acute Liver Failure (ALF).

Alcoholic and Non-Alcoholic Liver Disease (NAFLD) are chronic liver disease. Alcohol chronic consuption produced direct hepatotoxic injury -alcoholic liver disease (ALD). NAFLD is characterized by insulin resistance and obesity in the absence of not known alcohol misuse. The advanced form of ALD and NAFLD leads to inflammation of the liver resulting in alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH).

The discovery of non-invasive diagnostic biomarkers to identify patients with ALD and NAFLD who are prone to progress to ASH/NASH, cirrhosis and HCC is a task for the clinicians and laboratory medicine as well.

Scientists must work in concert to identify methods of surveillance for populations at risk. In this special issue we will update basic scientists and clinicians of the latest occurrences of this syndrome.

An additional aim is looking for possible use of nutrition, exercise and natural substances use in reducing the impact of ASH/NASH severity.

Prof. Neuman Manuela

Guest Editor

Prof. Dr. Manuela G. Neuman

In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, Faculty of Medicine, Banting Institute, University of Toronto, 100 College Street, Toronto, ON M5G 1L5, Canada

Deadline for manuscript submissions

closed (31 December 2020)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/44883

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).